For example, in patients with non-small-cell lung cancer (NSCLC), a dramatic increase of intracranial response rate was observed with tyrosine kinase inhibitors (TKIs) in epidermal growth factor rate (EGFR)-mutated patients [15,16]. Here, EGFR is linked to non-small cell lung carcinoma.